Ultivue’s Scientific Team Presents Compelling Tissue Marker Multiplexing Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ultivue has announced today the release of exciting new data
illustrating the performance of its proprietary InSituPlex™
that powers the company’s reagent offering. Ultivue’s
high- quality, kit-based products enable unsurpassed protein biomarker
detection and analysis in tissue, with no compromise on level of
multiplexing or sample staining and imaging throughput, and with no
requirement of dedicated instrumentation. Dr. Michael Natan, Ultivue’s
Chief Executive Officer, “We are very excited to demonstrate, through a
compelling data set, that our products provide the performance and
flexibility demanded in a wide range of use cases from clinical research
and translational research to discovery applications.”

Ultivue’s scientific team is presenting 4 posters at the Emerging
Proteomic Technologies for Cancer Research poster session on Wednesday
18 April, 2018 from 8:00 AM to 12.00 PM. Attendees at this important
meeting (April 14-18, Chicago, IL), will gain insight into how an array
of cancer types, including Non-Small Cell Lung Cancer (NSCLC), melanoma
and breast carcinomas, can easily be interrogated for the presence of
immuno-oncology markers using Ultivue’s ImmunoProfiler
on a single slide, and with single staining, signal
amplification, and imaging steps. The posters also illustrate
benchmarked equivalent performance vs. conventional DAB and TSA-based
immuno-histochemistry methods. However, compared to TSA-based
approaches, Ultivue’s InSituPlex
provides the important added benefits of (i) higher
multiplexing level on single slide for whole slide imaging, (ii)
dramatically improved usability, (iii) enhanced workflow integration,
and (iv) preservation of sample integrity for downstream experiments.

In addition to delivering excellent data quality, our assay panels
seamlessly integrate with common immunohistochemistry workflows to
deliver fast, high quality sample-to-image data. Up to 30 individual
tissue sample slides are routinely stained in our labs, as a single
batch, using an optimized, automated protocol. Within a work day, all 30
samples are stained and imaged as whole slides with a conventional
multispectral scanner”, says Philippe Mourere, SVP Commercial
Operations. “Such throughput provides significant gains of productivity
to those labs requiring fast and detailed sample-to-data tumor profiling
information”, adds Mourere.

Ultivue’s scientific personnel will be present at the company booth
#3402 throughout the duration of the meeting conference to engage with
the scientific community.

About Ultivue

Founded by two core faculty from the Wyss Institute at Harvard
University˗ David Walt, a world-leading expert in biomolecular analysis,
and Peng Yin, a pioneer in DNA nanotechnology˗ Ultivue is a
venture-backed company developing reagent-driven solutions for
high-performance biological imaging in situ, combining unlimited
multiplexing at high speed with high spatial resolution. Ultivue’s
proprietary solutions will enable researchers and clinicians to realize
the promise of personalized medicine through better matching of patients
to therapeutic options. The company is launching products and services
that seamlessly integrate into existing workflows for biomarker
discovery, assay validation, and companion diagnostic applications.
Ultivue is based in Cambridge, MA.
To learn more, visit www.ultivue.com


Ultivue Inc.
Louis Levy, +1-617-945-2662